Research - Newcastle upon Tyne, England, United Kingdom
GlycoScoreDx Limited is a diagnostic company developing a new blood test to revolutionise how prostate cancer is diagnosed. Built on over a decade of clinical and academic research, the GlycoScore Prostate Cancer Test uses a unique combination of biomarkers to provide a clear picture of clinically relevant prostate cancer, ruling out cancer in many cases, and ensuring that only patients with a clinically significant risk of the disease need to undergo the invasive procedure of painful prostate-tissue biopsy tests. Our technology is easily adoptable, and can be performed by any pathology lab using existing infrastructure.